Feb 17, 2026
GLP-1 receptor agonists have rewritten what pharmaceutical weight loss can accomplish. In the STEP 1 trial, adults taking semaglutide lost an average of nearly 15 percent of body weight over 68 weeks, compared with roughly 2 percent on placebo (Wilding et al., New England Journal of Medicine, 2021). Tirzepatide pushes those numbers higher still. But the scale does not distinguish fat from muscle, and when weight comes off this fast, some of what disappears is skeletal muscle, the tissue responsible for strength, resting metabolic rate, and functional independence as you age. That detail rarely makes it into the marketing, and it deserves an honest look.
How Much Muscle Actually Disappears
The numbers are consistent enough to take seriously. In the DXA substudy of STEP 1, fat mass fell by roughly 19 percent and visceral fat by around 27 percent. Lean mass declined too, in absolute terms, though its share of total body weight actually improved because fat came off faster (Wilding et al., 2021). Tirzepatide shows a similar pattern at greater scale. In the SURMOUNT-1 body composition substudy, participants lost 21.3 percent of body weight, with fat mass down 33.9 percent and lean mass down 10.9 percent. Of every kilogram lost, close to three quarters was fat and one quarter was lean tissue (Look, Dunn, Kushner et al., Diabetes, Obesity and Metabolism, 2025).
That one quarter figure holds up across the wider literature. A 2024 network meta-analysis of 22 randomized trials covering 2,258 participants found GLP-1 receptor agonists reduced lean mass by an average of 0.86 kilograms, close to a quarter of total weight lost, while relative lean mass as a share of body weight held steady (Metabolism, 2024). The same analysis found that tirzepatide 15 mg and semaglutide 2.4 mg, the most effective doses for fat loss, were among the least effective at preserving lean mass, while liraglutide was the only agent to produce significant weight loss without a significant lean mass reduction. A widely discussed commentary in The Lancet Diabetes and Endocrinology put the range even wider, at 25 to 39 percent of total weight lost across trials running 36 to 72 weeks, and noted this can exceed the pace of normal age related muscle loss by several times over (Prado, Phillips, Gonzalez, Heymsfield, 2024).
Why Losing Muscle Is Not Trivial
Skeletal muscle is not just for lifting. It is the body's largest site of glucose disposal, a major driver of resting metabolic rate, and the structural basis of grip strength, balance, and everyday function. Sarcopenia, the combination of low muscle mass with low strength or physical performance, carries real risk. A 2025 meta-analysis spanning more than 76,000 community dwelling older adults found sarcopenia nearly doubled the odds of both all-cause mortality (odds ratio 1.79) and functional decline (odds ratio 1.90). Against a baseline where muscle mass is already lost at roughly 0.6 to 1 percent per year in later life (Mitchell et al., Frontiers in Physiology, 2012), a drug driven acceleration is worth taking seriously.
There is an important nuance, though. In the SURPASS-3 MRI substudy, tirzepatide reduced thigh muscle volume by an amount broadly in line with the general aging population, while simultaneously reducing the fat stored inside the muscle itself, a change usually associated with better muscle quality and insulin sensitivity (Sattar, Neeland, Dahlqvist Leinhard et al., The Lancet Diabetes and Endocrinology, 2025). Muscle quantity and muscle quality are moving in different directions at the same time, which is why the net effect on real world strength remains genuinely unresolved rather than clearly harmful.
Expected, Not Exceptional
This is where honesty matters most. The prevailing expert view is that most GLP-1 associated muscle loss reflects the sheer size of the weight loss rather than a unique catabolic effect of the drugs themselves. Any large weight loss, whether from surgery, dieting, or medication, takes some lean mass with it. The authors of the Lancet commentary are explicit that this remains a hypothesis still to be tested, and that no evidence yet establishes these drugs cause physical frailty. The reasonable conclusion is not to avoid highly effective medications, but to pair them deliberately with the interventions that protect muscle.
What Actually Protects Muscle
Here the evidence is refreshingly unglamorous, and it predates GLP-1 drugs by decades.
Resistance training is the foundation. A meta-analysis of caloric restriction trials in obese older adults found that adding resistance training preserved roughly 93 percent of the lean mass that would otherwise have been lost (Sardeli et al., Nutrients, 2018). In a more extreme test, young men placed in a steep 40 percent energy deficit for four weeks, while lifting weights and doing interval training, actually gained lean mass on a higher protein intake while still losing fat (Longland, Oikawa, Mitchell, Devries, Phillips, American Journal of Clinical Nutrition, 2016).
Protein is the second lever, and arguably the most relevant one for GLP-1 users specifically. The International Society of Sports Nutrition recommends 1.4 to 2.0 grams of protein per kilogram of body weight daily to build and maintain muscle, with intakes toward 2.3 to 3.1 grams potentially needed to maximize lean mass retention during a calorie deficit (Jager, Kerksick, Campbell et al., 2017). This matters because reduced appetite on these drugs can quietly pull total intake, protein included, below target without anyone noticing. Higher protein has repeatedly been shown to blunt lean mass loss during weight loss, cutting it from 1.6 kilograms down to 0.3 kilograms in trained athletes in one trial (Mettler, Mitchell, Tipton, 2010).
Creatine monohydrate is the third lever. The ISSN position stand calls it the most effective ergogenic supplement available for increasing lean mass and high intensity exercise capacity, and considers it safe at standard doses for years of continuous use (Kreider, Kalman, Antonio et al., 2017). Its benefit shows up mainly alongside resistance training, and no trial has yet tested it directly in GLP-1 users, but the mechanistic case and long safety record are both strong.
The Natural GLP-1 Booster Problem
As these drugs went mainstream, a supplement industry bloomed around them, promising to boost the hormone naturally or shield muscle while using the real thing. This is where popular claims outrun the data by the widest margin.
Berberine, marketed as nature's Ozempic, does have real but modest metabolic effects. Most trials enroll fewer than 100 participants, run only 8 to 12 weeks, and measure glycemic or lipid endpoints rather than weight, and a 2020 systematic review of 35 studies concluded that robust weight loss evidence is lacking. Melinda Ring, an integrative medicine physician at Northwestern University's Feinberg School of Medicine, has called the nature's Ozempic label overblown, describing an effect on the order of five to ten pounds at most, a fraction of what semaglutide or tirzepatide deliver.
Oleoylethanolamide genuinely stimulates GLP-1 release from intestinal cells through the GPR119 receptor (Lauffer, Iakoubov, Brubaker, Diabetes, 2009), but its human weight loss data remain thin. A recent 12-week randomized, placebo controlled trial of 250 milligrams daily in 57 adults with obesity found a significant weight reduction only in the subgroup with a BMI under 35, not across the full study group.
Dietary fiber does genuinely raise endogenous GLP-1 through short chain fatty acids produced by gut bacteria (Tolhurst et al., Diabetes, 2012; Chambers et al., Gut, 2015), but the magnitude is far smaller than pharmacological agonism, and a 2026 scoping review of 52 human studies found the effect on circulating GLP-1 and satiety inconsistent across fiber types.
The honest bottom line is that none of these compounds has human outcome data showing it preserves muscle while someone is actually on a GLP-1 drug. That specific claim is a marketing extrapolation from mechanism, not a demonstrated finding. Fiber and protein remain worth prioritizing, but for reasons that stand on their own evidence, not because they substitute for the drug or reliably protect muscle on top of it.
The Next Frontier: Drugs That Spare Muscle
The most advanced pharmacological strategy blocks the activin and myostatin pathways that normally limit muscle growth. Bimagrumab, an antibody targeting this pathway, produced a 20.5 percent reduction in fat mass alongside a 3.6 percent gain in lean mass in a phase 2 trial in adults with type 2 diabetes and obesity (Heymsfield, Coleman, Miller et al., JAMA Network Open, 2021). Combined with semaglutide in the 2026 BELIEVE trial, the high dose pairing produced 22.1 percent weight loss with more than 92 percent of it coming from fat, compared with a 7.4 percent lean mass loss when semaglutide was used alone (Heymsfield, Aronne, Montgomery et al., Nature Medicine, 2026). Apitegromab, a selective myostatin inhibitor, cut lean mass loss by nearly 2 kilograms when added to tirzepatide in the 2026 EMBRAZE trial, despite similar total weight loss between groups.
These results are genuinely promising, but every one comes from a phase 2 trial, and at least one industry program combining tirzepatide with bimagrumab has already been discontinued for business reasons unrelated to safety. This entire drug class should be treated as investigational, not as something available or proven today.
The Practical Takeaway
If you are starting a GLP-1 drug, build the protective habits from day one rather than waiting for a scan to reveal a problem. Lift weights two to four times a week. Aim for protein around 1.6 grams per kilogram of body weight, moving higher if you are already lean and losing weight quickly. Consider 3 to 5 grams of creatine daily if you are training. Track body composition and grip strength over time rather than relying on the scale alone, since the scale cannot tell fat from muscle. And if you are older, losing weight faster than roughly a kilogram a week, or unable to hit your protein target because the drug has erased your appetite, bring a clinician and dietitian into the plan. These drugs are a powerful tool. Whether you keep your muscle depends largely on what you do around them.
References
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity: the STEP 1 randomized trial. New England Journal of Medicine. 2021;384(11):989-1002.
Look M, Dunn JP, Kushner RF, et al. Body composition changes with tirzepatide: a SURMOUNT-1 dual energy X-ray absorptiometry substudy. Diabetes, Obesity and Metabolism. 2025.
Network meta-analysis of GLP-1 receptor agonists and lean mass in 22 randomized controlled trials (2,258 participants). Metabolism. 2024.
Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes and Endocrinology. 2024;12(11):785-787.
Meta-analysis of sarcopenia and all-cause mortality and functional decline in community dwelling older adults (39 studies, 76,151 participants). 2025.
Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength. Frontiers in Physiology. 2012;3:260.
Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition: a SURPASS-3 magnetic resonance imaging substudy. The Lancet Diabetes and Endocrinology. 2025;13(6):482-493.
Sardeli AV, Komatsu TR, Mori MA, Gaspari AF, Chacon-Mikahil MPT. Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: a systematic review and meta-analysis. Nutrients. 2018;10(4):423.
Longland TM, Oikawa SY, Mitchell CJ, Devries MC, Phillips SM. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss. American Journal of Clinical Nutrition. 2016;103(3):738-746.
Jager R, Kerksick CM, Campbell BI, et al. International Society of Sports Nutrition position stand: protein and exercise. Journal of the International Society of Sports Nutrition. 2017;14:20.
Mettler S, Mitchell N, Tipton KD. Increased protein intake reduces lean body mass loss during weight loss in athletes. Medicine and Science in Sports and Exercise. 2010;42(2):326-337.
Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18.
Systematic review of berberine and metabolic outcomes across 35 studies. 2020.
Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. 2009;58(5):1058-1066.
Randomized, double blind, placebo controlled 12-week trial of oleoylethanolamide (250 mg daily) in 57 adults with obesity. 2025.
Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364-371.
Chambers ES, Viardot A, Psichas A, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance, and adiposity in overweight adults. Gut. 2015;64(11):1744-1754.
Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Network Open. 2021;4(1):e2033457.
Heymsfield SB, Aronne LJ, Montgomery R, et al. Bimagrumab plus semaglutide for weight loss with lean mass preservation: the BELIEVE phase 2 randomized trial. Nature Medicine. 2026;32(3):869-882.
Apitegromab plus tirzepatide for lean mass preservation during weight loss: the EMBRAZE phase 2 randomized trial. Nature Medicine. 2026.